Ibtehaj Ul-Haque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ibtehaj Ul-Haque has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Ishaque Hameed
Department of Medicine, MedStar Health, Baltimore, MD, USA
2 shared publications Mahnoor Sadiq
4th Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan
2 shared publicationsMisbah Munaf
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
2 shared publications- Taha Bin Arif
Department of Internal Medicine, Sinai Hospital of Baltimore, The George Washington University Regional Medical Campus, Baltimore, MD
2 shared publications - Abeeha Aimen
Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, PAK
1 shared publication - Aiman Anjum
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan
1 shared publication
Latest Publications
- 22 May 2024
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 135  (8) , 917-918
Navigating autism treatment: unlocking new frontiers with ChatGPT
Autism Spectrum disorder is a significant neurodevelopmental behavioral disorder. Children with Autism display a wide array of ambiguous symptoms resulting making the diagnosis quite challenging thus resulting in delayed management. Traditionally, its diagnosis and management require the collaboration of services from the three P's namely the pediatrician, psychiatrist, and child psychologist. The management requires an intensive multi-disciplinary approach which would help minimize the disease symptoms and facilitate development and learning during childhood.Recently, with the advent of widespread testing and usage of various artificial intelligence tools across various domains, AI tools such as Chatbots are being incorporated into medical treatments, especially in behavioral therapy. Considering the increasing use of AI, we believe that the natural language processing techniques employed by ChatGPT algorithms have the potential to identify speech and linguistic patterns in children with ASD. Therefore, through this letter, we have tried to explore the scope of Artificial intelligence (ChatGPT) for behavioral therapy in children affected with autism spectrum disorder.
- 22 May 2024
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 135  (8) , 917-918
Navigating autism treatment: unlocking new frontiers with ChatGPT
Autism Spectrum disorder is a significant neurodevelopmental behavioral disorder. Children with Autism display a wide array of ambiguous symptoms resulting making the diagnosis quite challenging thus resulting in delayed management. Traditionally, its diagnosis and management require the collaboration of services from the three P's namely the pediatrician, psychiatrist, and child psychologist. The management requires an intensive multi-disciplinary approach which would help minimize the disease symptoms and facilitate development and learning during childhood.Recently, with the advent of widespread testing and usage of various artificial intelligence tools across various domains, AI tools such as Chatbots are being incorporated into medical treatments, especially in behavioral therapy. Considering the increasing use of AI, we believe that the natural language processing techniques employed by ChatGPT algorithms have the potential to identify speech and linguistic patterns in children with ASD. Therefore, through this letter, we have tried to explore the scope of Artificial intelligence (ChatGPT) for behavioral therapy in children affected with autism spectrum disorder.
- Open Access
- 22 April 2024
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 74  (5) , 1027
Arfolitixorin: An unmet need in the management of metastatic colorectal cancer
Arfolitixorin [6R]-5,10-methylenetetrahydrofolate (6R-MTHF) is a folate-based contemporary prodrug that FDA has approved for Phase III study [1]. It is a refined form of folate, which boosts cytotoxic 5-fluorouracil (5-FU) competence, thereby enhancing tumor mortality in carcinoma cells. This drug is currently used in patients who underwent therapeutic regimens with advanced colorectal cancer (CRC) as reported by Isofol Medical AB [2]. Conventional treatment for advanced colorectal cancer relies on cytotoxic drugs initially, but drug resistance poses challenges. Chemotherapy, has systemic toxicity and lacks tumor specificity, driving the exploration of targeted therapies like monoclonal antibodies and immunotherapeutic approaches (ACT, vaccines, cytokines) to address limitations and enhance outcomes, thus this is where Arfolitixorin emerge as a potential treatment option [3]. Unlike traditional folate-based prodrugs like leucovorin and levoleucovorin, Arfolitixorin doesn't need multi-step metabolic activation, making it highly beneficial for advanced colorectal cancer patients. A genomic analysis at Östra Hospital in Gothenburg found that ~75% of metastatic colorectal cancer patients lack the potential to effectively metabolize folate-based drugs, rendering them ineffective, but Arfolitixorin provides a new ray of hope for these patients [2]. In a developing country like Pakistan, the prevalence of colorectal cancer is 5.6% [4]. Moreover, advanced mCRC with liver and lung involvement has a five-year survival of only 10-15%. Thus most patients with mCRC are treated with 5-FU. Following therapy, they become susceptible to the side-effects including anemia, diarrhea, bruising, bleeding, and mucositis etc. To counter such effects folinic acid is co-administered. Despite this regimen, the conversion of folinic acid to MTHF is inefficient, leading to suboptimal levels of MTHF. In such cases, a drug such as Arfolitixorin can be beneficial as it does not require conversion leading to a concurrent rise in MTHF levels in tumor cells thus causing efficient regression of tumor cells. Some potential adverse effects of Arfolitixorin include diarrhea, nausea, vomiting, stomatitis, leucopenia, neutropenia, thrombocytopenia, ocular toxicity, paresthesia, fatigue, and neuropathy, which seemed to be the equivalent of conventional folate based prodrugs and not more pronounced, eliciting it as a better treatment candidate due to its effectiveness [5]. Arfolitixorin can be considered a broad-spectrum medication for the standard-care treatment for metastasized & non-metastasized CRC as well as other cancers including breast cancer, pancreatic cancer, head and neck cancers, and stomach cancers because in such cancers conventional folate-based drugs are also administered. Further clinical trials must be conducted to predict the safety and efficiency of Arfolitixorin.
- 22 April 2024
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 74  (5) , 1027
Open AccessArfolitixorin: An unmet need in the management of metastatic colorectal cancer
Arfolitixorin [6R]-5,10-methylenetetrahydrofolate (6R-MTHF) is a folate-based contemporary prodrug that FDA has approved for Phase III study [1]. It is a refined form of folate, which boosts cytotoxic 5-fluorouracil (5-FU) competence, thereby enhancing tumor mortality in carcinoma cells. This drug is currently used in patients who underwent therapeutic regimens with advanced colorectal cancer (CRC) as reported by Isofol Medical AB [2]. Conventional treatment for advanced colorectal cancer relies on cytotoxic drugs initially, but drug resistance poses challenges. Chemotherapy, has systemic toxicity and lacks tumor specificity, driving the exploration of targeted therapies like monoclonal antibodies and immunotherapeutic approaches (ACT, vaccines, cytokines) to address limitations and enhance outcomes, thus this is where Arfolitixorin emerge as a potential treatment option [3]. Unlike traditional folate-based prodrugs like leucovorin and levoleucovorin, Arfolitixorin doesn't need multi-step metabolic activation, making it highly beneficial for advanced colorectal cancer patients. A genomic analysis at Östra Hospital in Gothenburg found that ~75% of metastatic colorectal cancer patients lack the potential to effectively metabolize folate-based drugs, rendering them ineffective, but Arfolitixorin provides a new ray of hope for these patients [2]. In a developing country like Pakistan, the prevalence of colorectal cancer is 5.6% [4]. Moreover, advanced mCRC with liver and lung involvement has a five-year survival of only 10-15%. Thus most patients with mCRC are treated with 5-FU. Following therapy, they become susceptible to the side-effects including anemia, diarrhea, bruising, bleeding, and mucositis etc. To counter such effects folinic acid is co-administered. Despite this regimen, the conversion of folinic acid to MTHF is inefficient, leading to suboptimal levels of MTHF. In such cases, a drug such as Arfolitixorin can be beneficial as it does not require conversion leading to a concurrent rise in MTHF levels in tumor cells thus causing efficient regression of tumor cells. Some potential adverse effects of Arfolitixorin include diarrhea, nausea, vomiting, stomatitis, leucopenia, neutropenia, thrombocytopenia, ocular toxicity, paresthesia, fatigue, and neuropathy, which seemed to be the equivalent of conventional folate based prodrugs and not more pronounced, eliciting it as a better treatment candidate due to its effectiveness [5]. Arfolitixorin can be considered a broad-spectrum medication for the standard-care treatment for metastasized & non-metastasized CRC as well as other cancers including breast cancer, pancreatic cancer, head and neck cancers, and stomach cancers because in such cancers conventional folate-based drugs are also administered. Further clinical trials must be conducted to predict the safety and efficiency of Arfolitixorin.
- Open Access
- 22 March 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 217
Safety of remimazolam in comparison with midazolam for colonoscopy: A systematic review and meta-analysis
Background Remimazolam is an ester-based ultra-short-acting benzodiazepine that efficiently achieves sedation within a short period and is now being assessed as a suitable alternative to midazolam. This meta-analysis aims to pool the available data assessing and focusing on the safety aspect of remimazolam compared with midazolam. Methods A multi-center randomized control trial for patients undergoing endoscopic procedures like colonoscopy was conducted, comparing remimazolam to placebo for the midazolam group as the intervention group. The safety of remimazolam was the primary endpoint of this meta-analysis. Results A total of 3 studies were included. The total study population was 697, including the placebo, remimazolam, and midazolam groups. The types of studies included are i. randomized, double-blind, parallel-group, active-controlled clinical trial ii. prospective, randomized, parallel-group study comparing remimazolam to placebo (blindly), RCT, and iii. prospective, double-blind, randomized, parallel-group study RCT.; Treatment-emergent adverse effects included vascular disorders (P=0.42), cardiac disorders (p=0.06), respiratory, thoracic, and mediastinal disorders (p=0.26), infections and infestations (0.88), hematologic abnormalities such as anemia (p=0.63), and derangements in Blood pressure (systolic p=0.47 and diastolic p=0.68 and respiratory parameters (p=0.34). Analysis of the reported data suggests that the remimazolam group had a significantly higher incidence of treatment-emergent adverse effects compared to the midazolam group (RR: 0.84; 95% CI [0.78, 0.91]; P <0.00001; I2 = 5%). Conclusions In conclusion, this meta-analysis of three randomized controlled trials showed outcomes favoring both remimazolam and midazolam as successful sedatives, yet the higher requirement of top-up dosage and rescue sedatives in the midazolam group indicates that remimazolam can be used as its replacement, especially in colonoscopy procedures.
- 22 March 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 217
Open AccessSafety of remimazolam in comparison with midazolam for colonoscopy: A systematic review and meta-analysis
Background Remimazolam is an ester-based ultra-short-acting benzodiazepine that efficiently achieves sedation within a short period and is now being assessed as a suitable alternative to midazolam. This meta-analysis aims to pool the available data assessing and focusing on the safety aspect of remimazolam compared with midazolam. Methods A multi-center randomized control trial for patients undergoing endoscopic procedures like colonoscopy was conducted, comparing remimazolam to placebo for the midazolam group as the intervention group. The safety of remimazolam was the primary endpoint of this meta-analysis. Results A total of 3 studies were included. The total study population was 697, including the placebo, remimazolam, and midazolam groups. The types of studies included are i. randomized, double-blind, parallel-group, active-controlled clinical trial ii. prospective, randomized, parallel-group study comparing remimazolam to placebo (blindly), RCT, and iii. prospective, double-blind, randomized, parallel-group study RCT.; Treatment-emergent adverse effects included vascular disorders (P=0.42), cardiac disorders (p=0.06), respiratory, thoracic, and mediastinal disorders (p=0.26), infections and infestations (0.88), hematologic abnormalities such as anemia (p=0.63), and derangements in Blood pressure (systolic p=0.47 and diastolic p=0.68 and respiratory parameters (p=0.34). Analysis of the reported data suggests that the remimazolam group had a significantly higher incidence of treatment-emergent adverse effects compared to the midazolam group (RR: 0.84; 95% CI [0.78, 0.91]; P <0.00001; I2 = 5%). Conclusions In conclusion, this meta-analysis of three randomized controlled trials showed outcomes favoring both remimazolam and midazolam as successful sedatives, yet the higher requirement of top-up dosage and rescue sedatives in the midazolam group indicates that remimazolam can be used as its replacement, especially in colonoscopy procedures.
- Top Cited PapersOpen Access
- 21 February 2023
- Published by Taylor & Francis in Medical Education Online
- Vol. 28  (1) , 2181052
The future of medical education and research: Is ChatGPT a blessing or blight in disguise?
To the editor,With the rapid evolution of scientific literature and technology, experts rely more on new artificial intelligence models for convenience and easy access to needs. The introduction of...
- 21 February 2023
- Published by Taylor & Francis in Medical Education Online
- Vol. 28  (1) , 2181052
Top Cited PapersOpen AccessThe future of medical education and research: Is ChatGPT a blessing or blight in disguise?
To the editor,With the rapid evolution of scientific literature and technology, experts rely more on new artificial intelligence models for convenience and easy access to needs. The introduction of...
- 10 May 2022
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 72  (5) , 1003
Use of subtle vibrations to predict future organ dysfunction
Over the years, the application of quantum physics in medicine has led to a greater understanding of the cellular processes within the human body. A dimension of quantum physics is vibration medicine. There is no distinction between energy and matter in quantum physics, and all molecules are constantly in motion, creating resonance. This resonance is critical to comprehending how subtle energy guides and maintains human health and fitness [1]. Subtle energies form the core of examination of the physiological and anatomical maps we examine in modern medicine. Evidence-based literature is present that depicts the relationship between subtle energies, mind-body connections, and electromagnetic waves [2]. Every cell in the body resonates and every part of the body has its sonic signature i.e. the sound of the cells of the heart is different from that of the cells of the lungs. It’s also seen those different forms of cell illnesses that affect humans have a unique frequency spectrum [3]. Subtle energy can be used to detect changes in the resonance of cells of the diseased organs and predict future organ dysfunction in patients with chronic diseases e.g. diabetes, and hypertension. In Pakistan, this diagnostic modality isn’t currently used, but it holds the potential to maximize preventative care and lessen the burden on its healthcare system. Hydrogels are cross-linked hydrophilic polymers similar to the extracellular matrix and adhere firmly to tissues [4]. The use of hydrogels in bio-medicine is of great interest [5]. However, there is insufficient literature that depicts the use of hydrogels in predicting future organ dysfunction. Zwitterionic Polydopamine-clay-poly [2-(methacryloyloxy) ethyl] dimethyl-(3-sulfopropyl) ammonium hydroxide (PDA-clay-PSMBA), a novel hydrogel, can be potentially used to predict future organ dysfunction. The novel hydrogel can adhere to a variety of body tissues with the strength of 19.4 KPa (in the heart). It retains firm adhesion on wet and underwater tissues and the adhesion is stable with heart beating and lung breathing. The hydrogel sensors monitor the dynamic vibrations of the organs, sending electrical impulses to the computer through wireless transmission. Excellent electrical conductivity, sensitivity, and robust adhesion allow it to detect subtle vibrations in the tissues. Moreover, the novel hydrogel is highly stretchable, self-healing, and bio-compatible [4]. Therefore, it holds considerable promise in detecting subtle vibrations which can then be used to predict future organ damage. More studies are needed to inspire vibratory medicine towards yielding results of possible organ dysfunctions by quantifying subtle vibrations.
- 10 May 2022
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 72  (5) , 1003
Use of subtle vibrations to predict future organ dysfunction
Over the years, the application of quantum physics in medicine has led to a greater understanding of the cellular processes within the human body. A dimension of quantum physics is vibration medicine. There is no distinction between energy and matter in quantum physics, and all molecules are constantly in motion, creating resonance. This resonance is critical to comprehending how subtle energy guides and maintains human health and fitness [1]. Subtle energies form the core of examination of the physiological and anatomical maps we examine in modern medicine. Evidence-based literature is present that depicts the relationship between subtle energies, mind-body connections, and electromagnetic waves [2]. Every cell in the body resonates and every part of the body has its sonic signature i.e. the sound of the cells of the heart is different from that of the cells of the lungs. It’s also seen those different forms of cell illnesses that affect humans have a unique frequency spectrum [3]. Subtle energy can be used to detect changes in the resonance of cells of the diseased organs and predict future organ dysfunction in patients with chronic diseases e.g. diabetes, and hypertension. In Pakistan, this diagnostic modality isn’t currently used, but it holds the potential to maximize preventative care and lessen the burden on its healthcare system. Hydrogels are cross-linked hydrophilic polymers similar to the extracellular matrix and adhere firmly to tissues [4]. The use of hydrogels in bio-medicine is of great interest [5]. However, there is insufficient literature that depicts the use of hydrogels in predicting future organ dysfunction. Zwitterionic Polydopamine-clay-poly [2-(methacryloyloxy) ethyl] dimethyl-(3-sulfopropyl) ammonium hydroxide (PDA-clay-PSMBA), a novel hydrogel, can be potentially used to predict future organ dysfunction. The novel hydrogel can adhere to a variety of body tissues with the strength of 19.4 KPa (in the heart). It retains firm adhesion on wet and underwater tissues and the adhesion is stable with heart beating and lung breathing. The hydrogel sensors monitor the dynamic vibrations of the organs, sending electrical impulses to the computer through wireless transmission. Excellent electrical conductivity, sensitivity, and robust adhesion allow it to detect subtle vibrations in the tissues. Moreover, the novel hydrogel is highly stretchable, self-healing, and bio-compatible [4]. Therefore, it holds considerable promise in detecting subtle vibrations which can then be used to predict future organ damage. More studies are needed to inspire vibratory medicine towards yielding results of possible organ dysfunctions by quantifying subtle vibrations.
- Open Access
- 12 April 2022
- Published by Springer Nature in Cureus
- Vol. 14  (4) , e24054
Transaxillary Versus Transaortic Transcatheter Aortic Valve Implantation in the Treatment of Aortic Stenosis: An Updated Systematic Review and Meta-Analysis
Transcatheter aortic valve replacement (TAVR) is a technique that can be performed through multiple approaches, and the benefits of one approach over another are still being evaluated to make sure patients receive the best possible care. Our meta-analysis aims to compare clinical and procedural outcomes of the transaxillary (TAx) and transaortic (TAo) approaches to validate the more optimal procedure. The systematic literature search was done via PubMed/MEDLINE, Embase, and the Cochrane Central databases from inception to December 2021, to identify articles reporting data on both TAx TAVR and TAo TAVR. In addition, we checked ClinicalTrials.gov for more published or unpublished trials. Baseline patient characteristics, procedure results, and clinical results were extracted from the article and pooled for analysis. A quantitative meta-analysis was conducted using Review Manager (RevMan) version 5.3 (Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). The outcomes extracted included blood transfusion, conversion to sternotomy, tamponade, contrast amount, procedure time, bleeding incidents (minor, major, or life-threatening), length of stay (LOS), vascular complications (minor or major), acute kidney injury (AKI), paravalvular leak (PVL), permanent pacemaker (PPM) implantation, 30-day mortality, one-year mortality, 30-day stroke, and device success. The final analysis included 11 articles, consisting of 10 observational studies and a pivotal trial. Cumulative results revealed that the TAo approach had a significantly lower incidence of vascular complications (RR = 2.30; 95% CI = 1.22 to 4.35), and the need for implantation of a permanent pacemaker (RR = 1.82; 95% CI = 1.30 to 2.54) along with a lower amount of contrast (mean difference (MD) = 27.40; 95% CI = 3.73 to 51.08) needed to be used. The TAx group was associated with a significantly lower 30-day mortality (RR = 0.46; 95% CI = 0.31 to 0.69), AKI (RR = 0.47; 95% CI = 0.33 to 0.67), and length of hospital stay (MD = −1.95; 95% CI = −2.51 to −1.38). No significant difference was observed between the outcomes of 30-day stroke (RR = 1.38; 95% CI = 0.81 to 2.33), PVL (RR = 1.05; 95% CI = 0.50 to 2.18), tamponade (RR = 0.71; 95% CI = 0.12 to 4.03), conversion to sternotomy (RR = 0.51; 95% CI = 0.06 to 4.30), device success (RR = 0.97; 95% CI = 0.88 to 1.07), the incidence of bleeding (RR = 0.75; 95% CI = 0.51 to 1.10), and procedure time (MD = 4.44; 95% CI = −96.30 to 105.17). Both the procedures were associated with their benefits and risks. Although most of the outcomes favored TAx transcatheter aortic valve implantation (TAVI), it is too early to say if it would be better than TAo TAVI. To authenticate the findings concluded in this meta-analysis and further improve our understanding of the efficacy, safety, and risk profile between TAx and TAo approaches for TAVI, large sample randomized clinical trials are required on a wide scale.
- 12 April 2022
- Published by Springer Nature in Cureus
- Vol. 14  (4) , e24054
Open AccessTransaxillary Versus Transaortic Transcatheter Aortic Valve Implantation in the Treatment of Aortic Stenosis: An Updated Systematic Review and Meta-Analysis
Transcatheter aortic valve replacement (TAVR) is a technique that can be performed through multiple approaches, and the benefits of one approach over another are still being evaluated to make sure patients receive the best possible care. Our meta-analysis aims to compare clinical and procedural outcomes of the transaxillary (TAx) and transaortic (TAo) approaches to validate the more optimal procedure. The systematic literature search was done via PubMed/MEDLINE, Embase, and the Cochrane Central databases from inception to December 2021, to identify articles reporting data on both TAx TAVR and TAo TAVR. In addition, we checked ClinicalTrials.gov for more published or unpublished trials. Baseline patient characteristics, procedure results, and clinical results were extracted from the article and pooled for analysis. A quantitative meta-analysis was conducted using Review Manager (RevMan) version 5.3 (Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). The outcomes extracted included blood transfusion, conversion to sternotomy, tamponade, contrast amount, procedure time, bleeding incidents (minor, major, or life-threatening), length of stay (LOS), vascular complications (minor or major), acute kidney injury (AKI), paravalvular leak (PVL), permanent pacemaker (PPM) implantation, 30-day mortality, one-year mortality, 30-day stroke, and device success. The final analysis included 11 articles, consisting of 10 observational studies and a pivotal trial. Cumulative results revealed that the TAo approach had a significantly lower incidence of vascular complications (RR = 2.30; 95% CI = 1.22 to 4.35), and the need for implantation of a permanent pacemaker (RR = 1.82; 95% CI = 1.30 to 2.54) along with a lower amount of contrast (mean difference (MD) = 27.40; 95% CI = 3.73 to 51.08) needed to be used. The TAx group was associated with a significantly lower 30-day mortality (RR = 0.46; 95% CI = 0.31 to 0.69), AKI (RR = 0.47; 95% CI = 0.33 to 0.67), and length of hospital stay (MD = −1.95; 95% CI = −2.51 to −1.38). No significant difference was observed between the outcomes of 30-day stroke (RR = 1.38; 95% CI = 0.81 to 2.33), PVL (RR = 1.05; 95% CI = 0.50 to 2.18), tamponade (RR = 0.71; 95% CI = 0.12 to 4.03), conversion to sternotomy (RR = 0.51; 95% CI = 0.06 to 4.30), device success (RR = 0.97; 95% CI = 0.88 to 1.07), the incidence of bleeding (RR = 0.75; 95% CI = 0.51 to 1.10), and procedure time (MD = 4.44; 95% CI = −96.30 to 105.17). Both the procedures were associated with their benefits and risks. Although most of the outcomes favored TAx transcatheter aortic valve implantation (TAVI), it is too early to say if it would be better than TAo TAVI. To authenticate the findings concluded in this meta-analysis and further improve our understanding of the efficacy, safety, and risk profile between TAx and TAo approaches for TAVI, large sample randomized clinical trials are required on a wide scale.
- Open Access
- 6 March 2022
- Published by Springer Nature in Cureus
- Vol. 14  (3) , e22881
Efficacy of Remimazolam for Procedural Sedation in American Society of Anesthesiologists (ASA) I to IV Patients Undergoing Colonoscopy: A Systematic Review and Meta-Analysis
Remimazolam is made by combining midazolam and remifentanil as an alternative to conventional sedatives. To evaluate the efficacy of remimazolam for sedation in patients undergoing colonoscopy, we conducted a systematic review and meta-analysis of the available randomized controlled trials (RCTs) comparing remimazolam and midazolam. A search was conducted using PubMed, Cochrane Library, and clinicaltrial.gov from inception till December 26, 2021, for RCTs that investigated the efficacy of remimazolam during the above-mentioned procedure. There was no restriction of language. A quality assessment was performed using the Cochrane Risk-of-Bias tool. The data were pooled, and a meta-analysis was completed. The systemic review was conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guideline statement. Three randomized controlled trials involving 539 patients were included in the meta-analysis. Compared with midazolam during colonoscopy, remimazolam results in reduced need for top-up doses (RR= 3.45, 95% CI=1.07 to 11.14; P=0.04, I2=84%). The need for rescue medication was reduced with remimazolam as compared to midazolam (RR=2.42, 95%CI=1.04 to 5.61; P=0.04, I2=96%). There was no significant difference observed between the two drugs on completion of colonoscopy and the overall procedural sedation, but the sensitivity analysis favored remimazolam over midazolam for procedural sedation (RR=4.08, 95%CI=2.35 to 7.09; P2=39%). This analysis demonstrates the advantages of remimazolam over other agents and sets a platform for relevant future studies.
- 6 March 2022
- Published by Springer Nature in Cureus
- Vol. 14  (3) , e22881
Open AccessEfficacy of Remimazolam for Procedural Sedation in American Society of Anesthesiologists (ASA) I to IV Patients Undergoing Colonoscopy: A Systematic Review and Meta-Analysis
Remimazolam is made by combining midazolam and remifentanil as an alternative to conventional sedatives. To evaluate the efficacy of remimazolam for sedation in patients undergoing colonoscopy, we conducted a systematic review and meta-analysis of the available randomized controlled trials (RCTs) comparing remimazolam and midazolam. A search was conducted using PubMed, Cochrane Library, and clinicaltrial.gov from inception till December 26, 2021, for RCTs that investigated the efficacy of remimazolam during the above-mentioned procedure. There was no restriction of language. A quality assessment was performed using the Cochrane Risk-of-Bias tool. The data were pooled, and a meta-analysis was completed. The systemic review was conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guideline statement. Three randomized controlled trials involving 539 patients were included in the meta-analysis. Compared with midazolam during colonoscopy, remimazolam results in reduced need for top-up doses (RR= 3.45, 95% CI=1.07 to 11.14; P=0.04, I2=84%). The need for rescue medication was reduced with remimazolam as compared to midazolam (RR=2.42, 95%CI=1.04 to 5.61; P=0.04, I2=96%). There was no significant difference observed between the two drugs on completion of colonoscopy and the overall procedural sedation, but the sensitivity analysis favored remimazolam over midazolam for procedural sedation (RR=4.08, 95%CI=2.35 to 7.09; P2=39%). This analysis demonstrates the advantages of remimazolam over other agents and sets a platform for relevant future studies.
- 11 March 2021
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 71  (7) , 1-8
Need of the hour: finding alternatives to a centralized Emergency Medical Services (EMS) system in Pakistan
The WHO recognizes Pakistan to be on of the top contributors to mortalities related to accidents and road trafiic injuries. The lack of awareness and education in the general population and lack of adequate training about Basic Life Support (BLS) and trauma management in healthcare professionals in Pakistan play a pivotal role in causing this grim situation. Lack of funds allocated to healthcare system specfically the Emergency services is one of the many root causes leading to a significant number of preventable mortalities. These injuries lead to lifelong and irreversible effects on both the physical and mental health of those involved. Moreover, it leads to unnecsserary strain on the already burdened healthcare system. Thus,immediate nationwide efforts are needed to create a system which is updated and capable enough to filter, classify and handle the emergencies. This system must be centralized, should be able to train people and make its own policies. This will ultimately lead to a better management at the emergency site and swift transitioning to the healthcare facility. Continuous.....
- 11 March 2021
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 71  (7) , 1-8
Need of the hour: finding alternatives to a centralized Emergency Medical Services (EMS) system in Pakistan
The WHO recognizes Pakistan to be on of the top contributors to mortalities related to accidents and road trafiic injuries. The lack of awareness and education in the general population and lack of adequate training about Basic Life Support (BLS) and trauma management in healthcare professionals in Pakistan play a pivotal role in causing this grim situation. Lack of funds allocated to healthcare system specfically the Emergency services is one of the many root causes leading to a significant number of preventable mortalities. These injuries lead to lifelong and irreversible effects on both the physical and mental health of those involved. Moreover, it leads to unnecsserary strain on the already burdened healthcare system. Thus,immediate nationwide efforts are needed to create a system which is updated and capable enough to filter, classify and handle the emergencies. This system must be centralized, should be able to train people and make its own policies. This will ultimately lead to a better management at the emergency site and swift transitioning to the healthcare facility. Continuous.....
- Open Access
- 30 June 2020
- Published by Springer Nature in Cureus
- Vol. 12  (6) , e8937
Congenitally Corrected Transposition of Great Arteries with Dextrocardia, Patent Ductus Arteriosus, Atrial Septal Defects and Ventricular Septal Defects in a 15-Year-Old Marfanoid Habitus Patient: A Case Study
Congenitally corrected transposition of the great arteries (CCTGA) is a rare congenital cardiac anomaly defined by atrio-ventricular and ventriculo-arterial discordance. This malformation makes up less than 1% of congenital heart defects. We report here a case of a 15-year-old female who presented to our hospital with dyspnea as seen in the New York Heart Association (NYHA) Functional Classification class III and hemoptysis. She was clinically found to have marfanoid habitus, and subsequent echocardiographic study disclosed CCTGA-associated with Ebstein's anomaly, ventricular septal defect, left ventricular outflow obstruction, right ventricular outflow obstruction, co-existing dextrocardia, atrial septal defect, patent ductus arteriosus, non-confluent pulmonary arteries, and pulmonary atresia. This case highlights the association between such rare cardiac conditions. To the best of our knowledge, this is the first case of CCTGA at a young age, with the aforementioned abnormalities documented in the literature reported from Pakistan.
- 30 June 2020
- Published by Springer Nature in Cureus
- Vol. 12  (6) , e8937
Open AccessCongenitally Corrected Transposition of Great Arteries with Dextrocardia, Patent Ductus Arteriosus, Atrial Septal Defects and Ventricular Septal Defects in a 15-Year-Old Marfanoid Habitus Patient: A Case Study
Congenitally corrected transposition of the great arteries (CCTGA) is a rare congenital cardiac anomaly defined by atrio-ventricular and ventriculo-arterial discordance. This malformation makes up less than 1% of congenital heart defects. We report here a case of a 15-year-old female who presented to our hospital with dyspnea as seen in the New York Heart Association (NYHA) Functional Classification class III and hemoptysis. She was clinically found to have marfanoid habitus, and subsequent echocardiographic study disclosed CCTGA-associated with Ebstein's anomaly, ventricular septal defect, left ventricular outflow obstruction, right ventricular outflow obstruction, co-existing dextrocardia, atrial septal defect, patent ductus arteriosus, non-confluent pulmonary arteries, and pulmonary atresia. This case highlights the association between such rare cardiac conditions. To the best of our knowledge, this is the first case of CCTGA at a young age, with the aforementioned abnormalities documented in the literature reported from Pakistan.
- Open Access
- 24 June 2019
- Published by Springer Nature in Cureus
- Vol. 11  (6) , e4982
The Role of Glycated Hemoglobin A1c in Determining the Severity of Coronary Artery Disease in Diabetic and Non-Diabetic Subjects in Karachi
Coronary artery disease is the leading cause of death worldwide by incidence. Over the years, many studies have been conducted to find predictors of coronary artery disease; however, in the last few decades, the level of HbA1c in diabetics has been investigated as a potential predictor. Our study offers additional insight by investigating similar relationships in non-diabetic patients and by investigating potential predictors more comprehensively, making it the first of its kind study. The aim of our study is to indicate that rising HbA1c levels suggest that there’s a greater risk of coronary artery disease, which can further be confirmed by the SYNTAX score, degree of stenosis, and numbers of vessels involved. Data from 177 diabetic and 378 non-diabetic patients, all of whom were above 18 years of age, were included in the research. HbA1c levels (>5.6%), SYNTAX score, hypertension, number of vessels involved, and other demographic elements, such as age, smoking, and body measurements, were calculated and compared for diabetics and non-diabetics. HbA1c was higher in comparison to non-diabetic subjects (p 53 was found to be a predictor for SYNTAX score ≥23 in diabetic patients (p <0.05). Male gender and smoking were found to be independent predictors for three-vessel disease in the non-diabetic population (p-value<0.05). There was no significant relationship between the SYNTAX score and HbA1c levels in non-diabetics (p=0.885) and diabetics. In conclusion, there is no correlation between elevated HbA1c levels and SYNTAX score ≥23.
- 24 June 2019
- Published by Springer Nature in Cureus
- Vol. 11  (6) , e4982
Open AccessThe Role of Glycated Hemoglobin A1c in Determining the Severity of Coronary Artery Disease in Diabetic and Non-Diabetic Subjects in Karachi
Coronary artery disease is the leading cause of death worldwide by incidence. Over the years, many studies have been conducted to find predictors of coronary artery disease; however, in the last few decades, the level of HbA1c in diabetics has been investigated as a potential predictor. Our study offers additional insight by investigating similar relationships in non-diabetic patients and by investigating potential predictors more comprehensively, making it the first of its kind study. The aim of our study is to indicate that rising HbA1c levels suggest that there’s a greater risk of coronary artery disease, which can further be confirmed by the SYNTAX score, degree of stenosis, and numbers of vessels involved. Data from 177 diabetic and 378 non-diabetic patients, all of whom were above 18 years of age, were included in the research. HbA1c levels (>5.6%), SYNTAX score, hypertension, number of vessels involved, and other demographic elements, such as age, smoking, and body measurements, were calculated and compared for diabetics and non-diabetics. HbA1c was higher in comparison to non-diabetic subjects (p 53 was found to be a predictor for SYNTAX score ≥23 in diabetic patients (p <0.05). Male gender and smoking were found to be independent predictors for three-vessel disease in the non-diabetic population (p-value<0.05). There was no significant relationship between the SYNTAX score and HbA1c levels in non-diabetics (p=0.885) and diabetics. In conclusion, there is no correlation between elevated HbA1c levels and SYNTAX score ≥23.